<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897192</url>
  </required_header>
  <id_info>
    <org_study_id>190318</org_study_id>
    <nct_id>NCT03897192</nct_id>
  </id_info>
  <brief_title>Long-term Outcome of Zonal Outer Retinopathy in Punctate Inner Choroidopathy or Multifocal Choroiditis</brief_title>
  <official_title>Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhua Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhua Christian Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To report the long term prognosis in patients with punctate inner choroidopathy (PIC) or
      multifocal choroiditis (MFC) and associated zonal outer retinopathy (ZOR).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">March 20, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Wilcoxon Signed-Rank test</measure>
    <time_frame>Baseline, 4 year</time_frame>
    <description>A statistical comparison of average of different time point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual acuity</measure>
    <time_frame>Baseline, 6 month, 12 month, 24 month, 36 month, 48 month</time_frame>
    <description>visual acuity change in logMAR in different time point</description>
  </secondary_outcome>
  <enrollment type="Actual">14</enrollment>
  <condition>Punctate Inner Choroidopathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Anti-vascular endothelial growth factor (VEGF)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We included patients of PIC/MFC and ZOR with a clinical follow up of 4 years or longer.
        Patients were recorded of age, sex, best corrected visual acuity (BCVA), refractive status,
        coexistence of choroidal neovascularization, number and total area of PIC/MFC lesions,
        treatment, and recurrent activity.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) and
             associated zonal outer retinopathy (ZOR).

          -  Follow up over 4 years.

        Exclusion Criteria:

          -  Patients with punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC)
             without zonal outer retinopathy (ZOR).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>March 28, 2019</last_update_submitted>
  <last_update_submitted_qc>March 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhua Christian Hospital</investigator_affiliation>
    <investigator_full_name>San Ni Chen</investigator_full_name>
    <investigator_title>Department of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>punctate inner choroidopathy</keyword>
  <keyword>multifocal choroiditis</keyword>
  <keyword>zonal outer retinopathy</keyword>
  <keyword>long-term outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroid Diseases</mesh_term>
    <mesh_term>Choroiditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

